3-(4-chlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide | 154674-97-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-chlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
• 英文别名: 5-(4-chlorophenyl)-3-(4-methylphenyl)-3,4-dihydropyrazole-2-carbothioamide
• CAS: 154674-97-2
• 化学式: C₁₇H₁₆ClN₃S
• 分子量: 329.853
• InChiKey: LNQLPJTUONOFGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  73.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide 、 溴乙酸 在 sodium acetate 、 乙酸酐 、 溶剂黄146 作用下， 以85%的产率得到2-(3-(4-chlorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one
  参考文献：
  名称：

  Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors

  摘要：

  A series of pyrazolyl-thiazolinone derivatives (E1-E36) have been designed and synthesized and their biological activities were also evaluated as potential EGFR and HER-2 kinase inhibitors. Thirty-four of the 36 compounds were reported for the first time. Among them, compound 2-(5-(4-bromophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one (E28) displayed the most potent inhibitory activity (IC50 = 0.24 mu M for EGFR and IC50 = 1.07 mu M for HER-2). Antiproliferative assay results indicated that compound E28 owned high antiproliferative activity against MCF-7, B16-F10 and HCT-116 in vitro, with IC50 value of 0.30, 0.54, and 0.70 mu M, respectively. Docking simulation was further performed to position compound E28 into the EGFR active site to determine the probable binding model. Based on the preliminary results, compound E28 with potent inhibitory activity in tumor growth would be a potential anticancer agent. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.051
• 作为产物：
  描述：

  对氯苯乙酮 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.17h， 生成 3-(4-chlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
  参考文献：
  名称：

  新型 1-(4-取代-噻唑-2-基)-3,5-二(杂)芳基-吡唑啉衍生物的合成和对人COX-1的选择性抑制活性

  摘要：

  3,5-二(杂)芳基-1-硫代氨基甲酰基-2-反应得到新型1-(4-乙基羧酸酯-噻唑-2-基)-3,5-二(杂)芳基-2-吡唑啉衍生物吡唑啉与α-溴-丙酮酸乙酯。合成的化合物通过光谱数据得到证实，并进行了分析，以评估它们在体外抑制人类环氧合酶 (hCOX) 两种异构体的能力。一些衍生物（化合物 5、6、13、16 和 17）在微摩尔范围内对 hCOX-1 显示出有希望的选择性，并且显示出与参考药物（吲哚美辛、双氯芬酸）相似或更好的选择性指数。在（4-取代-噻唑-2-基）吡唑啉衍生物的 C3 上与 4-取代苯基或杂芳基相连的 C5 上引入苯基或 4-F-苯环提高了对 hCOX-的活性1.

  DOI：

  10.1002/ardp.201200249

文献信息

• Recurrent π–π stacking motifs in three new 4,5-dihydropyrazolyl–thiazole–coumarin hybrids: X-ray characterization, Hirshfeld surface analysis and DFT calculations
  作者：Murtaza Madni、Muhammad Naeem Ahmed、Muhammad Hafeez、Muhammad Ashfaq、Muhammad Nawaz Tahir、Diego M. Gil、Bartomeu Galmés、Shahid Hameed、Antonio Frontera

  DOI：10.1039/d0nj02931a

  日期：——

  The synthesis and X-ray characterization of three new 4,5-dihydropyrazolylthiazole–coumarin hybrids (1–3) are reported herein, namely 3-(2-(3,5-bis(4-chlorophenyl)-4,5-dihydropyrazol-1-yl)thiazol-4-yl)-2H-chromen-2-one (1), 3-(2-(5-(4-chlorophenyl)-4,5-dihydro-3-phenylpyrazol-1-yl)thiazol-4-yl)-2H-chromen-2-one (2) and 3-(2-(3-(4-chlorophenyl)-4,5-dihydro-5-p-tolylpyrazol-1-yl)thiazol-4-yl)-2H-chromen-2-one

  本文报道了三种新的4,5-二氢吡唑基噻唑-香豆素杂化物（1-3）的合成和X射线表征，即3-（2-（3,5-双（4-氯苯基）-4,5-二氢吡唑） -1-基）噻唑-4-基）-2 H-铬-2- （1），3-（2-（5-（4-氯苯基）-4,5-二氢-3-苯基吡唑-1- yl）thiazol-4-yl）-2 H -chromen-2-one（2）和3-（2-（3-（4-chlorophenyl）-4,5-dihydro-5- p -tolylpyrazol-1-yl ）噻唑-4-基）-2 H-铬-2--2-（3）。还报告了非共价相互作用的详细结构分析及其使用Hirshfeld表面分析的评估，证明了C–H⋯O和π–π相互作用的重要性。最后，DFT计算以及分子静电势（MEP）和NCIplot指数分析已被用于大力评估这些相互作用，并研究了两种不同的π堆积模式的相对重要性，这些模式是循环结合基序在固体结构中的相对重要性。三个复合体。
• Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1 H )-pyrazole derivatives
  作者：Franco Chimenti、Simone Carradori、Daniela Secci、Adriana Bolasco、Bruna Bizzarri、Paola Chimenti、Arianna Granese、Matilde Yáñez、Francisco Orallo

  DOI：10.1016/j.ejmech.2009.11.003

  日期：2010.2

  A series of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives has been synthesized and assayed for their ability to inhibit the activity of the A and B isoforms of human monoamine oxidase (hMAO). Some of these compounds were endowed with a selective inhibitory activity against hMAO-B in the micromolar range. The most active of the series is the compound 13, N1-thiocarbamoyl-3-(fur-2'-yl)-5-(4'-fluoro-phenyl)-4,5-dihydro-(1H)-pyrazole, with IC50 2.75 +/- 0.81 mu M value and selectivity ratio of 25, which is the best candidate for further investigations. (C) 2009 Elsevier Masson SAS. All rights reserved.
• Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors
  作者：Ke-Ming Qiu、Hai-Hong Wang、Li-Ming Wang、Yin Luo、Xian-Hui Yang、Xiao-Ming Wang、Hai-Liang Zhu

  DOI：10.1016/j.bmc.2012.01.051

  日期：2012.3

  A series of pyrazolyl-thiazolinone derivatives (E1-E36) have been designed and synthesized and their biological activities were also evaluated as potential EGFR and HER-2 kinase inhibitors. Thirty-four of the 36 compounds were reported for the first time. Among them, compound 2-(5-(4-bromophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one (E28) displayed the most potent inhibitory activity (IC50 = 0.24 mu M for EGFR and IC50 = 1.07 mu M for HER-2). Antiproliferative assay results indicated that compound E28 owned high antiproliferative activity against MCF-7, B16-F10 and HCT-116 in vitro, with IC50 value of 0.30, 0.54, and 0.70 mu M, respectively. Docking simulation was further performed to position compound E28 into the EGFR active site to determine the probable binding model. Based on the preliminary results, compound E28 with potent inhibitory activity in tumor growth would be a potential anticancer agent. (C) 2012 Elsevier Ltd. All rights reserved.
• Synthesis and Selective Inhibitory Activity Against Human COX-1 of Novel 1-(4-Substituted-thiazol-2-yl)-3,5-di(hetero)aryl-pyrazoline Derivatives
  作者：Simone Carradori、Daniela Secci、Adriana Bolasco、Celeste De Monte、Matilde Yáñez

  DOI：10.1002/ardp.201200249

  日期：2012.12

  (compounds 5, 6, 13, 16, and 17) displayed promising selectivity against hCOX‐1 in the micromolar range and were shown to have a selectivity index similar or better than the reference drugs (indometacin, diclofenac). The introduction of a phenyl or a 4‐F‐phenyl ring on the C5 associated with a 4‐substituted phenyl or a heteroaryl group on the C3 of (4‐substituted‐thiazol‐2‐yl)pyrazoline derivatives improved

  3,5-二(杂)芳基-1-硫代氨基甲酰基-2-反应得到新型1-(4-乙基羧酸酯-噻唑-2-基)-3,5-二(杂)芳基-2-吡唑啉衍生物吡唑啉与α-溴-丙酮酸乙酯。合成的化合物通过光谱数据得到证实，并进行了分析，以评估它们在体外抑制人类环氧合酶 (hCOX) 两种异构体的能力。一些衍生物（化合物 5、6、13、16 和 17）在微摩尔范围内对 hCOX-1 显示出有希望的选择性，并且显示出与参考药物（吲哚美辛、双氯芬酸）相似或更好的选择性指数。在（4-取代-噻唑-2-基）吡唑啉衍生物的 C3 上与 4-取代苯基或杂芳基相连的 C5 上引入苯基或 4-F-苯环提高了对 hCOX-的活性1.